FutureMeds appoints Nachiket Chandak as Chief Commercial Officer

FutureMeds has appointed Nachiket Chandak as Chief Commercial Officer (CCO), a newly created role that will shape the group’s commercial strategy across service lines and strengthen alignment between commercial commitments and operational delivery. 

Nach joins the executive leadership team at a time when sponsors and CROs are asking trusted research partners to deliver faster, with greater predictability, while maintaining quality and compliance across countries and delivery models.  

This appointment supports FutureMeds’ next stage of growth as the organisation expands into new countries, broadens Therapeutic area expertise and capacity, and scales decentralised and hybrid delivery, while keeping reliability and service standards in lockstep with that growth. 

“FutureMeds is entering a new phase. More countries and sites, broader therapeutic coverage and a larger role for decentralised and hybrid delivery. That growth only matters if reliability, our values, and our ability to deliver on our commitments remain in step with scale. We are continuing to strengthen our teams with the right talent, both internal & external. Bringing Nach onto the executive team strengthens the specialised commercial leadership needed to help sponsors and CROs plan with confidence and to expand patient access to cutting-edge treatments in a more consistent way.” 

- Dr Radoslaw Janiak, CEO of FutureMeds

A role designed to strengthen how we partner with clients 

Clinical research delivery is becoming more complex, driven by protocol intensity, regulatory expectations, competitive recruitment environments and rising expectations around patient access and representation.  

As CCO, Nach will focus on how FutureMeds brings its capabilities to market while ensuring through stronger collaboration across the parties that feasibility, start-up planning and delivery governance are aligned early, reducing avoidable friction once studies are underway. 

“Sponsors and CROs don’t need more claims. They want predictable execution. My priority is to continue making working with FutureMeds simpler and more impactful: greater transparency between parties, reliable delivery at speed, and stronger governance with our partners. The goal is to help studies run with less risk and more predictability across Europe, so more patients can access trials and, where appropriate, potential new treatment options.” 

- Nachiket Chandak, Chief Commercial Officer at FutureMeds

He will work closely with operational leadership and country teams to strengthen account governance, enhance delivery pathways across service lines, and establish a strong operating rhythm with Sponsors and CROs across the network. 

What this means for sponsors and CROs 

Sponsors and CROs are operating in a tighter environment: complex protocols, tougher recruitment conditions, and higher expectations on quality and compliance across multiple countries and delivery models. In that context, what matters most is clarity early, fewer handoffs, and execution they can plan around.  

This appointment underscores our commitment to make FutureMeds simpler to work with. Clients should continue to expect enhanced alignment with their requirements and needs, as well as a tighter link between account strategy and execution planning. In practical terms, our commercial organisation will focus on: 

• More predictable multi-country execution planning 

• Increased strategic insights from the organisation 

• Better integration of decentralised and hybrid elements  

• Increased access to patient and site voice to support evidence-based planning  

• Stronger partnerships with greater accountability 
  

Nach’s background 

Nachiket previously served as Senior Director of Business Development at FutureMeds. He brings over 18 years of experience across the clinical research sector, including commercial roles supporting long-term partnerships with pharmaceutical and biotechnology organisations. 

Before joining FutureMeds, he held business development positions at major CRO’s such as PPD, ICON and Parexel, consistently contributing to revenue growth and progress for prominent organisations that shape the industry.